Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Summary

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

Timeline

Start

2020-08-17

Primary completion

2022-01-24

Completion

2022-07-22

Drugs

Indications